Croda completes acquisition of Solus Biotech

Croda International PLC
04 July 2023
 

Regulatory News Release

4 July 2023

Croda successfully completes acquisition of Solus Biotech

 

Croda International Plc ('Croda') today confirms that, following receipt of unconditional approval from the South Korean regulatory authorities, it has now successfully completed the acquisition of Solus Biotech, a global leader in premium, biotechnology-derived active ingredients for beauty care and pharmaceuticals.

 

This follows the announcement on 6 February 2023 that Croda had reached an agreement to acquire Solus Biotech.

 

-ENDS-

 

Further information:

Investors: David Bishop, Croda                                              +44 7823 874428

Media: Charlie Armitstead, Teneo                                          +44 7703 330269

 

About Croda:

Croda is the company that uses smart science to create high performance ingredients and technologies that improve lives. For more information see: www.croda.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Croda International (CRDA)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today